Highlights

  • Integral Diagnostics (ASX:IDX) closed at AUD 2.28, up 1.79% on 20 August 2026.
  • The company provides diagnostic imaging services across Australia and New Zealand.
  • Preliminary FY26 results indicated Revenue of approximately AUD 788 million to AUD 790 million, up about 25% year-on-year.
  • Investors continue to monitor Capitol Health integration, imaging demand, AI adoption and Balance Sheet improvement.

Integral Diagnostics Limited (ASX:IDX) shares closed at AUD 2.28, up 1.79% on 20 August 2026. The movement reflects a positive Trading session as investors continue to assess the company’s diagnostic imaging platform, Acquisition integration progress and healthcare services growth strategy.

Daily share price movements can reflect changes in investor sentiment, trading activity, valuation expectations and broader market conditions. However, a single-session movement does not necessarily indicate a change in the company’s underlying fundamentals, financial position or long-term operating outlook.

Integral Diagnostics provides diagnostic imaging services including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray and other imaging procedures across Australia and New Zealand. The company operates through a network of clinics serving patients, referrers and healthcare providers.

The broader Australian market closed higher on the day. The S&P/ASX 200 (ASX:XJO) closed at 9,083.80 points, up 0.33% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,019.90 points, up 0.37% today. Within the healthcare sector, the S&P/ASX 200 Health Care (ASX:XHJ) closed at 32,044.30 points, up 1.39% today.

Diagnostic imaging healthcare platform

Integral Diagnostics operates within the healthcare services sector, providing medical imaging services across Australia and New Zealand. The company’s operations include radiology clinics, specialist reporting services and technology-enabled imaging solutions.

The company’s Business model is supported by patient volumes, Medicare-funded services, private healthcare Demand and referral relationships with medical professionals.

Investors generally assess diagnostic imaging companies through factors such as patient volumes, imaging mix, margins, clinic utilisation, radiologist capacity and operational efficiency.

Integral Diagnostics expanded its scale through the acquisition of Capitol Health, creating a larger diagnostic imaging network. Investors continue to monitor integration progress, expected synergies and the company’s ability to improve efficiency across the combined platform.

The diagnostic imaging sector is also being influenced by technological developments, including artificial intelligence (AI), digital workflows and teleradiology solutions designed to improve reporting efficiency and patient access.

FY26 update and investor focus

Integral Diagnostics provided a preliminary FY26 results update highlighting expected revenue of approximately AUD 788 million to AUD 790 million, representing growth of about 25% compared with FY25 revenue of AUD 628.0 million. The increase reflects a full-year contribution from Capitol Health compared with approximately six months in the prior year.

Operating EBITDA is expected to be approximately AUD 164 million to AUD 165 million, up around 30% from AUD 126.5 million in FY25. Operating EBITDA Margin is expected to be approximately 20.8% to 21.0%, compared with 20.1% in FY25.

Operating NPAT is expected to reach approximately AUD 47 million to AUD 48 million, up around 50% from AUD 31.6 million in FY25. Diluted operating Earnings Per Share are expected to be approximately 12.5 cents to 12.7 cents, compared with 10.2 cents in FY25.

The company reported that net Debt to operating EBITDA improved to an estimated 2.3 times at 30 June 2026, compared with 2.6 times at 30 June 2025. Group replacement and growth Capital Expenditure was approximately AUD 50 million during FY26, within the company’s guidance range of AUD 45 million to AUD 55 million.

Integral Diagnostics also announced the appointment of Jenny Martin as incoming Chief Financial Officer as part of its Leadership transition. The company stated that audited FY26 results are scheduled for release after completion of year-end procedures and external audit review.

The company continues to focus on organic earnings growth, radiologist recruitment, productivity improvements, teleradiology expansion, digital capability and further realisation of benefits from the Capitol Health integration.

Factors investors generally monitor

Integral Diagnostics’ performance is influenced by healthcare demand, patient volumes, Medicare funding, referral activity and operational efficiency.

Patient Volume growth is an important Factor because diagnostic imaging businesses generate revenue through completed scans and reporting services. Investors generally monitor demand trends across MRI, CT, ultrasound and other imaging categories.

The integration of Capitol Health remains a key consideration. Acquisitions can increase scale and provide operational benefits, but investors assess whether expected synergies are achieved while maintaining service quality.

Radiologist availability and productivity are also important. Imaging providers require specialist medical professionals to support reporting capacity and manage growing healthcare demand.

Technology adoption is another area of focus. AI tools and teleradiology platforms can improve workflow efficiency and support broader access to diagnostic services.

Capital management remains relevant following acquisition activity. Investors monitor leverage, cash generation and the company’s ability to balance growth Investment with debt reduction.

Understanding the share price movement

Integral Diagnostics’ 1.79% share price increase on 20 August 2026 may reflect changes in investor sentiment, trading activity or positioning within the healthcare sector. However, daily share price movements alone do not necessarily represent changes in the company’s underlying fundamentals.

Healthcare services stocks can experience short-term movements as investors reassess earnings growth, acquisition outcomes, sector demand and operational performance.

For Integral Diagnostics, investors are likely to continue monitoring the final FY26 results, Capitol Health integration, margin performance and progress in digital healthcare initiatives.

Conclusion

Integral Diagnostics (ASX:IDX) closed at AUD 2.28, up 1.79% on 20 August 2026. The company continues to expand its diagnostic imaging platform across Australia and New Zealand through clinic operations, technology adoption and strategic integration.

While the daily share price movement reflects market activity, investors generally assess Integral Diagnostics through broader factors including imaging demand, revenue growth, EBITDA margins, acquisition synergies, Leverage management and healthcare technology adoption. The preliminary FY26 update highlighted higher revenue expectations, improved profitability metrics and continued focus on operational efficiency.